{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Haque R"],"funding":["California Breast Cancer Research Program"],"pagination":["e71642"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12936983"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(3)"],"pubmed_abstract":["<h4>Background</h4>Although nearly half of women with metastatic breast cancer (mBC) have hypertension, it is unclear whether hypertension management improves survival. We examined the influence of pharmacologic hypertension management on all-cause and breast cancer-specific mortality in patients with mBC.<h4>Methods</h4>We conducted a longitudinal cohort study of 1332 female patients with de novo mBC diagnosed 2008-2020, followed through 2021. We calculated person-year (PY) rates of all-cause and breast cancer mortality by use of antihypertensives (monotherapy or polytherapy [one vs. multiple drug classes]). Multivariable Cox regression was used to estimate the association between antihypertensives and mortality.<h4>Results</h4>Overall, 48.4% of patients with mBC had hypertension, which w"],"journal":["Cancer medicine"],"pubmed_title":["Influence of Hypertension Management on Survival in Patients With Metastatic Breast Cancer."],"pmcid":["PMC12936983"],"funding_grant_id":["B28TR5470"],"pubmed_authors":["Barac A","Hogan TA","Silverman A","Chen LH","Brady-Rogers M","Gu Z","Mukherjee A","Haque R","Wallner LP"],"additional_accession":[]},"is_claimable":false,"name":"Influence of Hypertension Management on Survival in Patients With Metastatic Breast Cancer.","description":"<h4>Background</h4>Although nearly half of women with metastatic breast cancer (mBC) have hypertension, it is unclear whether hypertension management improves survival. We examined the influence of pharmacologic hypertension management on all-cause and breast cancer-specific mortality in patients with mBC.<h4>Methods</h4>We conducted a longitudinal cohort study of 1332 female patients with de novo mBC diagnosed 2008-2020, followed through 2021. We calculated person-year (PY) rates of all-cause and breast cancer mortality by use of antihypertensives (monotherapy or polytherapy [one vs. multiple drug classes]). Multivariable Cox regression was used to estimate the association between antihypertensives and mortality.<h4>Results</h4>Overall, 48.4% of patients with mBC had hypertension, which w","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Mar","modification":"2026-07-16T21:55:12.622Z","creation":"2026-07-12T03:07:28.554Z"},"accession":"S-EPMC12936983","cross_references":{"pubmed":["41744234"],"doi":["10.1002/cam4.71642"]}}